pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
Company details
- Status
- Public
- HQ
- 770 Lindaro Street, San Rafael, CA 94901, US
- Founded
- 1997
- Employees
- 3,171
- Programs
- 91
- Drugs
- 36
- Patents
- 175
Quick answer
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hypochondroplasia. NovaPharmaNews links 91 clinical program(s), 10 drug profile(s), and 175 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (41), phase 3 (27), approved (10).
Company snapshot
BioMarin Pharmaceutical Australia maintains 91 tracked programs across Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hypochondroplasia, Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Hemophilia A, MPS IV A, Jansky-Bielschowsky Disease, Autistic Disorder, Phenylketonurias. Momentum score: 35/100 (30-day delta: n/a). Public registry data covers pipeline pha
- 15 approved product(s) across US/EU regulatory metadata.
- 91 active pipeline program(s) linked via ClinicalTrials.gov.
- 175 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for BioMarin Pharmaceutical Australia. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
BioMarin's Strategic Move: Voxzogo Label Expansion Insights
- approval
BioMarin's SWOT Analysis: Competitive Headwinds in Rare Disease Biotech
- approval
BioMarin Seeks Approval for Voxzogo in Short Stature Indication
- approval
BioMarin's SWOT Analysis: Competitive Challenges Ahead
- approval
This Week’s Biopharma News: New Approvals, Appeals, and AI
- approval
BioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams
Recent coverage
BioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams
BioMarin Pharmaceutical's rare disease therapy failed to show clinical benefit in a Phase 3 trial, triggering a reassessment of R&D strategy and investor confidence. This article covers key takeaways, regulatory implications, and actionable insights for pharma business development and regulatory teams.
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
BioMarin's SWOT Analysis: Competitive Challenges Ahead
This article delves into BioMarin's SWOT analysis, highlighting competitive challenges and implications for investors and pharma teams.
BioMarin's Strategic Move: Voxzogo Label Expansion Insights
BioMarin Pharmaceutical aims to expand Voxzogo's label following a successful trial. This article analyzes the competitive implications for pharma teams.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- approved
- approved
Momentum
Proprietary activity score for BioMarin Pharmaceutical Australia.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for BioMarin Pharmaceutical Australia.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is BioMarin Pharmaceutical Australia?
-
Is BioMarin Pharmaceutical Australia publicly traded?
-
What drugs does BioMarin Pharmaceutical Australia develop or market?
-
What are the latest developments for BioMarin Pharmaceutical Australia?
-
What therapeutic areas does BioMarin Pharmaceutical Australia focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.